title: Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents?
abstract: We describe a patient with severe psoriasis and hepatitis C simultaneously treated with pegylated interferon alpha (peg-IFNα) plus ribavirin and etanercept, whose skin lesions improved and who reached a sustained virological response. This case suggests that refractory psoriasis can today no longer be considered as a contraindication for combined hepatitis C virus treatment.
authors.affiliation: SOD Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. bartalesif@aou-careggi.toscana.it
authors.forename: Filippo
authors.initials: F
authors.lastname: Bartalesi
authors.forename: Elena
authors.initials: E
authors.lastname: Salomoni
authors.forename: Annalisa
authors.initials: A
authors.lastname: Cavallo
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Corti
authors.forename: Nicola
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bartoloni
authors.forename: Gloria
authors.initials: G
authors.lastname: Taliani
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D000075202:Contraindications; D000068800:Etanercept; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000821:virology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D007074:Immunoglobulin G; D016898:Interferon-alpha; D018124:Receptors, Tumor Necrosis Factor; D012254:Ribavirin; D000068800:Etanercept